These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27236498)

  • 1. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
    Lieberman PL; Umetsu DT; Carrigan GJ; Rahmaoui A
    J Allergy Clin Immunol; 2016 Sep; 138(3):913-915.e2. PubMed ID: 27236498
    [No Abstract]   [Full Text] [Related]  

  • 2. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
    Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
    Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
    Evans MO; Morris MJ; Coop CA; Evans SE
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
    Gönül M; Özenergün Bittacı A; Ergin C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
    [No Abstract]   [Full Text] [Related]  

  • 5. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an anaphylactoid reaction to omalizumab.
    Dreyfus DH; Randolph CC
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):624-7. PubMed ID: 16680936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
    Novosad J; Krčmová I
    Int J Immunopathol Pharmacol; 2020; 34():2058738420942386. PubMed ID: 32689848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
    Rams A; Żółciński M; Zastrzeżyńska W; Polański S; Serafin A; Wilańska J; Musiał J; Bazan-Socha S
    J Asthma; 2018 Dec; 55(12):1384-1386. PubMed ID: 29300536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics.
    Lieberman PL; Jones I; Rajwanshi R; Rosén K; Umetsu DT
    J Allergy Clin Immunol; 2017 Dec; 140(6):1734-1736.e4. PubMed ID: 28797731
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
    Lin RY; Rodriguez-Baez G; Bhargave GA
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):442-5. PubMed ID: 19927545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
    Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C
    Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388
    [No Abstract]   [Full Text] [Related]  

  • 14. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
    Limb SL; Starke PR; Lee CE; Chowdhury BA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1378-81. PubMed ID: 17936893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of idiopathic anaphylaxis with omalizumab.
    Sanchez-Valenzuela MC; Garcia-Saucedo JC; Motoa G; Carrillo-Martin I; Gonzalez-Estrada A
    Ann Allergy Asthma Immunol; 2019 Dec; 123(6):612-613. PubMed ID: 31568858
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate.
    Perino E; Freymond N; Devouassoux G; Nicolas JF; Berard F
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):664-666. PubMed ID: 29481891
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab.
    Yung S; Han D; Lee JK
    Can Respir J; 2015; 22(6):315-6. PubMed ID: 26401982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.